<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5411">
  <stage>Registered</stage>
  <submitdate>28/01/2000</submitdate>
  <approvaldate>28/01/2000</approvaldate>
  <nctid>NCT00004218</nctid>
  <trial_identification>
    <studytitle>Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia</studytitle>
    <scientifictitle>Chronic Lymphocytic Leukemia Trial 4: A Randomized Comparison of Chlorambucil, Fludarabine and Fludarabine Plus Cyclophosphamide</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>LRF-CLL4</secondaryid>
    <secondaryid>CDR0000067454</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Leukemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - chlorambucil
Treatment: drugs - cyclophosphamide
Treatment: drugs - doxorubicin hydrochloride
Treatment: drugs - fludarabine phosphate
Treatment: drugs - prednisolone
Treatment: drugs - vincristine sulfate

Treatment: drugs: chlorambucil


Treatment: drugs: cyclophosphamide


Treatment: drugs: doxorubicin hydrochloride


Treatment: drugs: fludarabine phosphate


Treatment: drugs: prednisolone


Treatment: drugs: vincristine sulfate


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Diagnosis of B-cell chronic lymphocytic leukemia (CLL) requiring therapy and meeting
             the following criteria:

               -  Previously untreated disease

               -  Peripheral blood morphology, excluding other leukemia and low-grade lymphoma in
                  leukemic phase

               -  Cell markers: CD5+, CD23+, SmIg (weak), CD79b-, FMC7-

               -  Persistent lymphocytosis (greater than 10,000/mm^3)

               -  At least 40% bone marrow infiltration

          -  Stage 0 or I progressive disease indicated by at least one of the following:

               -  Persistent rise in lymphocyte count with doubling time less than 12 months

               -  Downward trend in hemoglobin and/or platelet count

               -  At least 50% increase in size of liver and/or spleen and/or lymph nodes

               -  Appearance of lymphadenopathy, hepatomegaly, or splenomegaly

               -  Constitutional symptoms caused by disease

                    -  Pyrexia

                    -  Night sweats

                    -  Weight loss OR

          -  Stage II or III

        PATIENT CHARACTERISTICS:

        Age:

          -  Not specified

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  See Disease Characteristics

        Hepatic:

          -  Bilirubin no greater than 2 times upper limit of normal (ULN)*

          -  SGOT/SGPT no greater than 2 times ULN* NOTE: * Unless due to CLL

        Renal:

          -  Creatinine clearance at least 30 mL/min

        Other:

          -  No other cancer or life-threatening disease

          -  Not pregnant

          -  Fertile patients must use effective contraception during and for 6 months after study
             therapy

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  No concurrent corticosteroids (e.g., dexamethasone) as antiemetics

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/1999</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Zagreb</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Ioannina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Rio Patras</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Galway</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bergamo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>England</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Northern Ireland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Scotland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Wales</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Leukemia Research Fund</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Medical Research Council</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. It is not yet known which regimen of chemotherapy is more
      effective for chronic lymphocytic leukemia.

      PURPOSE: This randomized phase III trial is studying chlorambucil to see how well it works
      compared to fludarabine and cyclophosphamide or fludarabine alone in treating patients with
      newly diagnosed chronic lymphocytic leukemia.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00004218</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Daniel Catovsky, MD</name>
      <address>Royal Marsden NHS Foundation Trust</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>